These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 11487714)

  • 1. Population pharmacokinetics and dynamics in phase II studies of the novel bioreductive alkylating cytotoxic indoloquinone EO9.
    Schellens JH; Dombernowsky P; Cassidy J; Epelbaum R; Dirix L; Cox EH; Wanders J; Calabresi F; Paridaens R; Monfardini S; Wolff J; Loos WJ; Verweij J; Pavlidis N; Hanauske AR;
    Anticancer Drugs; 2001 Aug; 12(7):583-90. PubMed ID: 11487714
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I pharmacokinetics and limited sampling strategies for the bioreductive alkylating drug EO9. EORTC Early Clinical Trials Group.
    McLeod HL; Graham MA; Aamdal S; Setanoians A; Groot Y; Lund B
    Eur J Cancer; 1996 Aug; 32A(9):1518-22. PubMed ID: 8911111
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical studies with EO9, a new indoloquinone bioreductive alkylating cytotoxic agent. EORTC Early Clinical Trials Group.
    Verweij J; Aamdal S; Schellens J; Koier I; Lund B
    Oncol Res; 1994; 6(10-11):519-23. PubMed ID: 7620220
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I and pharmacologic study of the novel indoloquinone bioreductive alkylating cytotoxic drug E09.
    Schellens JH; Planting AS; van Acker BA; Loos WJ; de Boer-Dennert M; van der Burg ME; Koier I; Krediet RT; Stoter G; Verweij J
    J Natl Cancer Inst; 1994 Jun; 86(12):906-12. PubMed ID: 8196081
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Population pharmacokinetic and dynamic analysis of the topoisomerase I inhibitor lurtotecan in phase II studies.
    Schellens JH; Heinrich B; Lehnert M; Gore ME; Kaye SB; Dombernowsky P; Paridaens R; van Oosterom AT; Verweij J; Loos WJ; Calvert H; Pavlidis N; Cortes-Funes H; Wanders J; Roelvink M; Sessa C; Selinger K; Wissel PS; Gamucci T; Hanauske AR
    Invest New Drugs; 2002 Feb; 20(1):83-93. PubMed ID: 12003197
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics, distribution, and metabolism of the novel bioreductive alkylating indoloquinone EO9 in rodents.
    Workman P; Binger M; Kooistra KL
    Int J Radiat Oncol Biol Phys; 1992; 22(4):713-6. PubMed ID: 1544843
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I trial with weekly EO9, a novel bioreductive alkylating indoloquinone, by the EORTC Early Clinical Study Group (ECSG).
    Aamdal S; Lund B; Koier I; Houten M; Wanders J; Verweij J
    Cancer Chemother Pharmacol; 2000; 45(1):85-8. PubMed ID: 10647507
    [TBL] [Abstract][Full Text] [Related]  

  • 8. EO9: a novel bioreductive alkylating indoloquinone with preferential solid tumour activity and lack of bone marrow toxicity in preclinical models.
    Hendriks HR; Pizao PE; Berger DP; Kooistra KL; Bibby MC; Boven E; Dreef-van der Meulen HC; Henrar RE; Fiebig HH; Double JA
    Eur J Cancer; 1993; 29A(6):897-906. PubMed ID: 8484984
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacological properties of a new aziridinylbenzoquinone, RH1 (2,5-diaziridinyl-3-(hydroxymethyl)-6-methyl-1,4-benzoquinone), in mice.
    Loadman PM; Phillips RM; Lim LE; Bibby MC
    Biochem Pharmacol; 2000 Apr; 59(7):831-7. PubMed ID: 10718341
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics and early clinical studies of selected new drugs.
    Kaye SB; Workman P; Graham MA; Cassidy J; Jodrell D
    Cancer Surv; 1993; 17():371-96. PubMed ID: 8137348
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relative importance of DT-diaphorase and hypoxia in the bioactivation of EO9 by human lung tumor cell lines.
    Plumb JA; Gerritsen M; Milroy R; Thomson P; Workman P
    Int J Radiat Oncol Biol Phys; 1994 May; 29(2):295-9. PubMed ID: 8195022
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacological and biochemical determinants of the antitumour activity of the indoloquinone EO9.
    Cummings J; Spanswick VJ; Gardiner J; Ritchie A; Smyth JF
    Biochem Pharmacol; 1998 Feb; 55(3):253-60. PubMed ID: 9484790
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development, pharmacology, role of DT-diaphorase and prospects of the indoloquinone EO9.
    Smitskamp-Wilms E; Hendriks HR; Peters GJ
    Gen Pharmacol; 1996 Apr; 27(3):421-9. PubMed ID: 8723519
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bioreductive agents: a clinical update.
    Boyer MJ
    Oncol Res; 1997; 9(6-7):391-5. PubMed ID: 9406245
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of a novel in vitro assay for assessing drug penetration into avascular regions of tumours.
    Phillips RM; Loadman PM; Cronin BP
    Br J Cancer; 1998 Jun; 77(12):2112-9. PubMed ID: 9649122
    [TBL] [Abstract][Full Text] [Related]  

  • 16. EO9 phase II study in advanced breast, gastric, pancreatic and colorectal carcinoma by the EORTC Early Clinical Studies Group.
    Dirix LY; Tonnesen F; Cassidy J; Epelbaum R; ten Bokkel Huinink WW; Pavlidis N; Sorio R; Gamucci T; Wolff I; Te Velde A; Lan J; Verweij J
    Eur J Cancer; 1996 Oct; 32A(11):2019-22. PubMed ID: 8943690
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A novel strategy for NQO1 (NAD(P)H:quinone oxidoreductase, EC 1.6.99.2) mediated therapy of bladder cancer based on the pharmacological properties of EO9.
    Choudry GA; Stewart PA; Double JA; Krul MR; Naylor B; Flannigan GM; Shah TK; Brown JE; Phillips RM
    Br J Cancer; 2001 Oct; 85(8):1137-46. PubMed ID: 11710826
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chemosensitivity to the indoloquinone EO9 is correlated with DT-diaphorase activity and its gene expression.
    Smitskamp-Wilms E; Peters GJ; Pinedo HM; van Ark-Otte J; Giaccone G
    Biochem Pharmacol; 1994 Apr; 47(8):1325-32. PubMed ID: 7514407
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Unusually marked hypoxic sensitization to indoloquinone EO9 and mitomycin C in a human colon-tumour cell line that lacks DT-diaphorase activity.
    Plumb JA; Workman P
    Int J Cancer; 1994 Jan; 56(1):134-9. PubMed ID: 8262670
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reductase enzyme expression across the National Cancer Institute Tumor cell line panel: correlation with sensitivity to mitomycin C and EO9.
    Fitzsimmons SA; Workman P; Grever M; Paull K; Camalier R; Lewis AD
    J Natl Cancer Inst; 1996 Mar; 88(5):259-69. PubMed ID: 8614004
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.